Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors: A Clinical Investigation
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Objective Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the usual conditions of clinical practice, and to identify clinical predictors of the syndrome. Methods Ninety-seven outpatients who received an initial diagnosis of dysthymic disorder, who responded to >or=8 weeks treatment with paroxetine (n = 52) or fluoxetine (n = 45), and who discontinued the SSRI according to their psychiatrist's instructions were included. They were assessed at the time of discontinuation using a semi-structured interview for clinical and treatment characteristics, the Hamilton Depression Rating Scale (HAM-D) and the Montgomery-Asberg Depression Rating Scale (MADRS). Patients were then assessed 4 weeks later using a checklist for discontinuation symptoms, a semi-structured interview for discontinuation symptom characteristics, and the HAM-D and the MADRS. Results A discontinuation syndrome was found in 26 patients (26.8% of our sample); of this group, 22 patients (84.6%) had received paroxetine, and 4 patients (15.4%) had received fluoxetine. The mean time at onset of symptoms was 2 days after drug discontinuation and the mean duration was 5 days. The statistical comparison between the groups with and without a discontinuation syndrome found t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“randomised studies with a tapering period up to 14 days showed either no or minimal reduction in withdrawal symptom severity compared with abrupt discontinuation (Baldwin 2006;Bogetto 2002;Montgomery 2004a).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Bogetto 2002
In the citing paper
“Medications with shorter half-lives, like paroxetine, produce withdrawal symptoms with greater incidence 5,[15][16][17][18] , quicker onset 5,[15][16][17][18] , and greater severity 5,[15][16][17][18] than medications with longer half-lives, like fluoxetine 5,15,17,18 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [15]
In the citing paper
“SSRI withdrawal symptoms occur in many patients, with reported incidence rates varying from 42-100% for paroxetine 5,[15][16][17][18] , to 9-77% for fluoxetine 5,15,17,18 , and median rates of 53.6% for SSRIs across 14 studies that examined antidepressant withdrawal 13 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [15]
In the citing paper
“Results, obtained according to the patients' relapse status, showed no differences in neurological and psychiatric symptoms between individuals switched to placebo and those who continued with the active treatment.”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [33]
In the citing paper
“The duration of treatment might be as short as 2 months [33,39,42] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [33]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Research works printed but not linked: 10
- Diamond, 1989, Psychopharmacol Bull, 25, 209
- Halle, 1993, J Psychiatry Neurosci, 18, 49
- Stoukides, 1991, Am J Psychiatry, 148, 1263
- Black, 1993, J Clin Psychiatry, 54, 146
- Einbinder, 1995, Am J Psychiatry, 152, 1235
- Frost, 1995, Am J Psychiatry, 152, 810
- Kasantikul, 1995, J Med Assoc Thai, 78, 53
- Pyke, 1995, Am J Psychiatry, 152, 149
- Berlin, 1996, J Clin Psychiatry, 57, 93
- Black, 2000, J Psychiatry Neurosci, 25, 255
Cited by
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
“, 1993) at 4 weeks (Bogetto et al., 2002) at six weeks (Zajecka et al.”
BackgroundAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
The Antidepressant Sertraline: A Review of Its Uses in a Range of Psychiatric and Medical Conditions
Khouzam, H. R., Emes, R., Gill, T. S., & Raroque, R. (2003) · Comprehensive Therapy · doi:10.1007/s12019-003-0007-6 · Cited by 181
Metadata
- Authors
- Bogetto, F., Bellino, S., Revello, R. B., & Patria, L.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Bellino, Silvio
- ORCID
- Bellino, Silvio
- Venue
- CNS Drugs
- Published
- 2002
- Volume
- 16
- Issue
- 4
- Pages
- 273-283
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W21422233
- Semantic Scholar
- 7c26a42e847c61785a1e02bb85b182f6d6e5dd84
- Cited by
- 80
- References
- 50
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- discontinuation syndrome, selective serotonin reuptake inhibitors, dysthymia, paroxetine, fluoxetine, antidepressant discontinuation, age at onset of depression, sex differences
- MeSH terms
- Adolescent, Adult, Aged, Female, Fluoxetine, Humans, Interview, Psychological, Male, Middle Aged, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Time Factors, Selective Serotonin Reuptake Inhibitors, Paroxetine, Antidepressive Agents, Second-Generation, Dysthymic Disorder
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors: A Clinical Investigation. https://app.cochat.ai/papers/10.2165/00023210-200216040-00006
- The paper
- Bogetto, F., Bellino, S., Revello, R. B., & Patria, L. (2002). Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors: A Clinical Investigation. CNS Drugs. https://doi.org/10.2165/00023210-200216040-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.